Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-CART for SLE
NCT03030976Phase 1Unknown
- Sponsor
- Shanghai Genechem
- Start
- Mar 2017
- Primary completion
- Jan 2018
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19 CAR-T cells in systemic lupus erythematosus (SLE), sponsored by Shanghai Genechem. Primary endpoint: Safety of CAR-T cell (i.v.) by number of patients with adverse event at 6 weeks. Status: unknown.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03030976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03030976.